Neoadjuvant intralesional triamcinolone is not associated with increased incidence of surgical site complications in dogs with cutaneous and subcutaneous mast cell tumors.

NIT is safe perioperatively in dogs with MCTs and may reduce tumor size.

This retrospective study evaluated the safety of neoadjuvant intralesional triamcinolone (NIT) in dogs undergoing surgical excision of cutaneous and subcutaneous mast cell tumors (MCTs). Sixty-nine dogs with 78 MCTs were included, with NIT administered within 30 days of surgery. Overall surgical site complications (SSCs) occurred in 25% of cases, with 90% classified as minor complications. Notably, tumors receiving ≥2 triamcinolone injections had significantly lower SSC incidence (0%) compared to single injection (36%). No significant associations were found between SSC incidence and triamcinolone dose, injection timing, tumor characteristics, perioperative medications, or bandaging practices. Among tumors with documented response, 65% demonstrated size reduction with median reduction of 40%. The findings suggest NIT administration does not increase short-term postoperative incisional complications and may provide additional benefit through tumor size reduction and decreased peritumoral inflammation, supporting its use as an adjunctive therapy in canine MCT management.

This summary was distilled by AI and may occasionally misinterpret data. Confirm critical details with the primary literature before clinical application.